Kornimate/medical-research-clean huggingface dataset:
a ct-based deep learning model for predicting who/isup pathological grades of clear cell renal cell carcinoma (ccrcc) :a multicenter cohort study

Conditions: Tumor Grading; Deep Learning; Clear Cell Renal Cell Carcinoma

Summary: this study aims to establish an effective deep learning model to extract relevant information about renal tumors and kidneys from computed tomography (ct) images and predict the pathological grades of clear cell renal cell carcinoma (ccrcc). retrospective data were collected from 483 ccrcc patients across three medical centers. arterial phase and portal venous phase ct images from the dataset were segmented for renal tumors and kidneys. three convolutional neural networks (cnns) were employed to extract features from the regions of interest (roi) in the ct images across multiple dimensions including 3d, 2.5d, and 2d. least absolute shrinkage and selection (lasso) regression was used for feature selection. the models were evaluated using receiver operating characteristic (roc) curves and decision curve analysis (dca).


Eligibility criteria:
inclusion criteria: * patients with a single kidney tumor have complete imaging and clinical data * contrast-enhanced ct scan within 30 days before surgery * no treatment was performed before ct examination exclusion criteria: * patients with tumor recurrence * obvious artifacts on ct images * the tumor is cystic * multiple cysts on the affected kidney affect the delineation of renal parenchyma
evaluate the muscle protection effect of sevoflurane sedation in vascular surgery

Conditions: Vascular Surgery

Summary: halogenated anaesthetic agents (haa) may induce protective processes by pre-conditioning the myocardium. all of the literature shows that haa induce pre-conditioning, thanks to a class effect, and sevoflurane is the most widely used today. in humans, the protective effects of halogenated agents have principally been studied in heart surgery and have shown encouraging clinical results. it seems that haa induce both pre-conditioning of the myocardium (early and late) and post conditioning. given these protective effects of haa, in 2007, the american heart association (aha) recommended the use of haa for anaesthesia maintenance in non-cardiac surgery in patients with a high cardio-vascular risk. the aim of this study is to show a decrease in rhabdomyolysis and tissue distress (kidneys, myocardium and liver), thanks to sevoflurane anaesthesia, in the post-operative period following vascular surgery with clamping


Eligibility criteria:
inclusion criteria: * persons who have provided written consent * patients over 18 years of age * patients undergoing scheduled vascular surgery with high clamping for: * abdominal aortic aneurysm * suprapopliteal vascular bypass (aorto-bi-femoral, femoral trifurcation, ilio-femoral or femoro-femoral, femoro-popliteal). exclusion criteria: * persons without health insurance cover * patients younger than 18 years of age, pregnant or breast-feeding women and adults under guardianship * patients with epilepsy * emergency surgery * patient presenting a contra-indication for sevoflurane: hypersensitivity to sevoflurane or to other halogenated anaesthetic agents, myopathy, hyper-eosinophilia, immunoallergic hepatitis, known or suspected genetic predisposition to malignant hyperthermia * patients presenting a contra-indication to the use of propofol: known hypersensitivity to propofol or to one of the constituents of the product, allergy to peanuts or soja * patients presenting a contra-indication for sufentanil: hypersensitivity to sufentanil or to opioids * association with opioid agonists-antagonists or partial opioid antagonists * patients presenting a ci for the use of cisatracurium: history of allergy or hypersensitivity to cisatracurium or atracurium * patients presenting cardiac, respiratory, renal or kidney failure, hypovolemia, poor general health * patients with a risl of prolongation of the qt interval * patients with end-stage renal failure - requiring dialysis
double-blind, randomized, placebo-controlled study of low dose oral interferon alfa-n3 (human leukocyte derived) in arc patients

Conditions: HIV Infections

Summary: to conduct a parallel-group, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of an orally administered low dose interferon alfa-n3 as an immunomodulator in the treatment of mild to moderate symptomatic hiv+, aids-related complex (arc) patients.

the study has been extended to offer 52 weeks of maintenance therapy after the 10 weeks of the placebo controlled period are concluded successfully.

Eligibility criteria:
inclusion criteria concurrent medication: allowed: * zidovudine (azt). patients must have: * diagnosis of aids related complex (arc). * given written informed consent. * been receiving a dose of = or \< 600 mg/day of zidovudine (azt) at least 90 days prior to study entry if they are currently taking azt. prior medication: allowed: * zidovudine (azt) at a dose = or \< 600 mg/day at least 90 days prior to study entry. exclusion criteria co-existing condition: patients with the following conditions or symptoms are excluded: * history of aids-defining condition or evidence of aids dementia. * evidence of chronic hepatitis with severe liver dysfunction, or other active gastrointestinal, renal, respiratory, endocrine, hematologic, cardiovascular or psychiatric disorder that would limit the subject's ability to complete the 12 weeks of the study period. concurrent medication: excluded: * ketoconazole. * trimethoprim / sulfamethoxazole (tmp/smx). * experimental medications. patients with the following are excluded: * absolute cd4 count of \ 350 cells/mm3. * any disease or disorder listed in patient exclusion co-existing conditions. * unlikely or unable to comply with the requirements of the protocol. * unwilling or unable to give informed consent. * development of antibodies to interferon during prior interferon therapy that occurred \> 3 months prior to study entry. prior medication: excluded within 45 days of study entry: * immunomodulators (e.g., bcg vaccine, isoprinosine). * chemotherapy. * steroids. * excluded within 3 months of study entry: * interferon therapy. active iv drug abuse.

Keywords: acquired immunodeficiency syndrome aids-related complex interferon type i, recombinant
role of surgery for the primary in patients with breast cancer stage iv.

Conditions: Carcinoma Breast Stage IV

Summary: the purpose of this study is to determine benefits of surgery for the primary in patients with breast cancer stage iv in randomized controlled study.


Eligibility criteria:
inclusion criteria: * healthy breast cancer stage iv patients with resectable primary breast tumor. * resectable breast cancer stage iv patients who well response of visceral metastasis to systemic therapy and fit for surgery. exclusion criteria: * breast cancer stage iv patients with local complication of primary breast tumor that require surgery for palliation such as uncontrolled bleeding,large and non-healing ulcer or intractable pain. * breast cancer stage iv patients with unresectable primary breast tumor or extensive chest wall disease.
whole breast rt on prone position in korean women

Conditions: Breast Cancer

Summary: it is well known fact that postoperative whole breast radiation therapy (rt) in left breast cancer patient can cause cardiac problem according to the exposed dose. in the several studies in other countries, it was repeatedly showed that rt on prone position can reduce cardiac exposed rt dose in left breast cancer. however, the effectiveness of prone position in rt is not studied in the korean women have relatively small breast. the investigators planned this study to evaluate the real efficacy of prone position in korean breast cancer treated with rt.


Eligibility criteria:
inclusion criteria: * pathologically confirmed left breast cancer * 20 or older age * less than 70 years old * after curative resection * eastern cooperative oncology group performance status 0 to 1 * informed consent to this study * consent to contraception for 6 months after rt completion exclusion criteria: * male breast cancer * combined distant metastasis * status of pregnant or brest feeding * previous rt history of chest or neck area * indication of supraclavicular rt * not indicated postoperative whole breast rt

Keywords: korean left side
sphenopalatine blockade versus clinical treatment

Conditions: Headache, Post-Dural Puncture

Summary: post-dural puncture headache leads to high morbidity and cost to the health system. pregnant women have a higher incidence than other population groups. there are several treatments for post dural puncture headache mentioned in the literature, not all well established, with a wide heterogeneity of treatment between services. sphenopalatine block then appears as an alternative treatment, having been described as effective in reports and case series, requiring comparative experimental studies.

post-dural puncture headache leads to high morbidity and cost to the health system. pregnant women have a higher incidence than other population groups. there are several treatments for post dural puncture headache mentioned in the literature, not all well established, with a wide heterogeneity of treatment between services. sphenopalatine block then appears as an alternative treatment, having been described as effective in reports and case series, requiring comparative experimental studies. objectives: to evaluate the efficacy of sphenopalatine blockade in combination with multimodal treatment in reducing the incidence of epidural blood patch and pain intensity in patients who develop headache after dural puncture, compared with the clinical treatment in our service. methods: a prospective randomized clinical, analytical study will be conducted at the obstetric center of the central institute of the university of são paulo school of medicine hospital das clínicas (ichc-fmusp). women will be included who will undergo neuroaxis block for cesarean section, vaginal delivery or uterine curettage, and who later present headache after dural puncture, after evaluation and diagnosis by anesthesiologist. the patients will be divided into three groups at random. in group i, patients will receive clinical treatment according to the institution's old protocol for post dural puncture headache. in group ii, patients will receive clinical treatment, according to the new protocol of the institution. in group iii patients will receive clinical treatment, according to the new protocol of the institution, associated with sphenopalatine block. they will be reevaluated after 12, 24 and 48 hours, and a visual analog scale will be applied to evaluate improvement. the pain will be quantified before and after treatment. pain intensity will be evaluated by verbal numerical scale (evn), incidence of need for epidural blood buffer in each group, as well as length of hospital stay (in days).

Eligibility criteria:
inclusion criteria: * women who will undergo neuroaxis block for cesarean section, vaginal delivery or uterine curettage, and who later present with cerebrospinal fluid hypotension headache, after evaluation and diagnosis by anesthesiologist. exclusion criteria: * patients previously diagnosed with chronic headache; patients with contraindication for neuraxial anesthesia, patients with contraindication for any drugs involved in the study and users of psychotropic intravenous drugs.
neonatal intensive care (nicu) course and hospital outcome of infants with bpd treated using inhaled nitric oxide

Conditions: Bronchopulmonary Dysplasia

Summary: this is a chart review study of neonates admitted to primary children's medical center or university of utah nicu who had or developed a diagnosis of bronchopulmonary dysplasia (bpd) and were treated for this condition with inhaled nitric oxide (ino) beginning after the 4th week of life. for this study bpd will be defined as need for supplemental oxygen on day 28 of life. the data collection from the medical record will gather demographics on admission (birth weight, gestational age, etc); past medical history from transferring hospitals; admission diagnoses; hospital respiratory care treatment course and laboratory/xray findings; nutrition and growth; and discharge diagnoses including all major neonatal morbidities such as absence or severity of intraventricular hemorrhage, retinopathy of prematurity, or hearing deficits. the data will be compiled and compared to data previously published on similar infants with bpd but not treated with ino.

recent studies (e.g. schreiber 2003)1 have prompted several large current clinical trials on the use of inhaled nitric oxide (ino) for the prevention of bronchopulmonary dysplasia (bpd) in preterm infants. results of these studies are not yet published and will be forthcoming spring 2006. however, there is evidence to suggest that for patients with bpd, treatment with ino may improve oxygenation2 and improve pulmonary blood flow by relaxing pulmonary vascular tone. 3 also, there is a recent primate study that suggests in the face of existing bpd, treatment with ino may decrease oxygen and ventilation requirements through a mechanism that helps preserve surfactant protein.4 taken together, this preliminary work suggests there may be clinical benefit in treating established bpd with ino. however, as few data exist on the clinical course of bpd patients treated with ino, further description is necessary to evaluate ino as a potential treatment modality for bpd. since ino has been used as adjunctive therapy for neonates at pcmc with serious respiratory disease, useful information on the relationship between bpd and ino treatment may exist within our own patient population

Eligibility criteria:
inclusion criteria: * any patient who at 28 days of life was requiring oxygen therapy in the neonatal intensive care unit and who was then treated with ino would be eligible for chart review. since ino therapy has only been available for a few years, this study will attempt to capture all patients who qualify. exclusion criteria: * any patient who received ino treatment under an irb study protocol after 28d of life would not be eligible for chart review.

Keywords: chronic lung disease bronchopulmonary dysplasia inhaled nitric oxide premature infants
radial extracorporeal shock wave therapy versus high power pain threshold ultrasound therapy in supraspinatus tendinitis

Conditions: Supraspinatus Tendinitis

Summary: extra corporeal shock wave therapy is a treatment method in which high-amplitude sound waves are focused on the targeted body tissue recently, extra corporeal shock wave therapy has been proposed as an alternative treatment in patients not responding to pharmaceutical treatment.high power pain threshold ultrasound is the use of therapeutic ultrasound in a continuous mode; with the probe placed directly on affected area (supraspinatus tendon)

shock wave therapy is an effective method of dissolving calcification and stimulating tissue healing. extra corporeal shock wave therapy is a treatment method in which high-amplitude sound waves are focused on the targeted body tissue recently, extra corporeal shock wave therapy has been proposed as an alternative treatment in patients not responding to pharmaceutical treatment.us have been widely used for more than 40 years in the treatment of musculoskeletal disorders such as tendinitis, tenosynovitis, epicondylitis, bursitis and osteoarthritis. high power pain threshold ultrasound is the use of therapeutic ultrasound in a continuous mode; with the probe placed directly on affected area (supraspinatus tendon) "the intensity of ultrasound is first increased to the threshold pain level (to 1.5 w/cm) and then reduced to one half of that intensity. it was kept at that level for 4 to 5 seconds and then reduced to the half-intensity level for another 15 seconds .

Eligibility criteria:
inclusion criteria: * patients' age ranges from 30 to 50 years old. * patients are males and females. * bmi of all subjects were \<30 kg/m2. * patients will be diagnosed as supraspinatus tendinitis. * all patients are medically stable. * all patients should be conscious and ambulant. * patients don't have any nervous system problems * patients don't have shoulder disorder other than tendenities * patients that didn't undergo any surgery in shoulder joint exclusion criteria: * • patients who received intra articular injection from duration less than 3 months. * patients with supraspinatus tendonitis secondary to trauma. * patients with metal implants. * patient who had malignancy in the affected area. * patient with acute infection in the treated area. * diabetic patients * bone infection * shoulder instability * epilepsy * coagulation diseases * rheumatological diseases (rheumatoid arthritis and gouty arthritis)

Keywords: extracorporeal shock wave high power pain threshold ultrasound
cannabis and cancer, an online training for oncology nurses

Conditions: Cannabis Use; Cannabis Use, Unspecified; Nurse's Role; Oncology Pain; Symptoms and Signs

Summary: the purpose of this study is to evaluate the preliminary effects and impacts of a digital educational intervention to support nurses' professional practice regarding safe cannabis use by young adults (18-39 years) diagnosed with cancer.

this online pilot randomized controlled trial with parallel groups is conducted in quebec (canada). moodle learning management system will be used to train nurses working in oncology. after accepting the conditions and consenting, participants will enroll in the study by providing an email address. each participant will be validated through an email address check. after their enrolment, participants will receive a hyperlink via email to invite them to complete a baseline questionnaire. after completing the baseline questionnaire, participants will be randomly assigned by a research assistant to the digital educational intervention (cannabis \& cancer) or to a control group (official public websites and scientific articles). four weeks after the baseline questionnaire, participants will complete the online questionnaires again.

Eligibility criteria:
inclusion criteria: * work in an oncology department (eg, radio-oncology, outpatient clinics) * work with people diagnosed with cancer, including young adults * understand, read, and write french exclusion criteria: * none
comparison of bag-valve-guedel adaptor to common face mask for the ventilation of bearded men

Conditions: Pre-hospital Ventilation

Summary: ventilation of a bearded patient with the commonly used face mask has low efficiency because of difficulties to achieve a tight seal around the mouth and nose. the purpose of this study is to evaluate the efficacy of a novel bag valve guedel adaptor (bvga) that enables the direct connection of a bag valve device to a guedel - eliminating the need for a face mask.

ventilating a patient using a bag valve and a face mask is not easy to perform, especially for a long period of time, and mandates experience and strength by the care giver. the need for a tight seal around the mouth and nose is a major challenge especially if the patient has a beard. nevertheless, the face mask is the only approved respiratory support that medics and other basic care givers are allowed to use in the out-of-the-hospital setting, and only physicians and paramedics are allowed to use more advanced techniques, providing a definite airways. thus, despite its lower effectiveness, the bag valve mask technique is the most commonly used in the field the purpose of this study is to evaluate the efficacy of a novel bag valve guedel adaptor (bvga) that enables the direct connection of a bag valve device to a guedel - eliminating the need for a face mask. study design: prospective, randomized, controlled. the volunteers will be asked randomly assigned to breathe through the bvga/face mask followed by the same protocol with the face-mask/bvga: 5 minutes room air, 5 minutes 100% oxygen, and 5 minutes room air again. the bvgas/face masks well be connected to a standard operating room ventilation machines, and cardiopulmonary parameters will be monitored and documented.

Eligibility criteria:
inclusion criteria: 1. healthy males more than 18 years of age. 2. 22 with beards, 3 without beards. exclusion criteria: 1. presence of facial fractures or injuries. 2. claustrophobia. 3. respiratory diseases. 4. severe illness such as cardiac or neurological diseases.
effect of lugol's solution in the patients with graves' disease

Conditions: Graves Disease

Summary: context: although some of endocrine surgeons administer lugol's solution to decrease thyroid gland vascularity, there is still no agreement on its effectiveness. objective: the aims of this clinical trial are to evaluate thyroid blood flow and microvessel density in the patients with graves' disease according to the lugol's solution treatment preoperatively. design: retrospective clinical trial. setting: a tertiary referral center. method: thirty-six patients were randomly assigned to preoperative medication with lugol's solution. patients in group 1 (n=17) received lugol's solution for 10 days before surgical intervention, whereas patients in group 2 (n=19) didn't receive it. main outcome measures: blood flow through the thyroid arteries of patients with graves' disease was measured by color flow doppler ultrasonography. the microvessel density (mvd) was assessed immunohistochemically and western blot analysis using the level of expression of cd-34 in thyroid tissue. the thyroid gland's weight and blood loss were measured in all patients.

thirty-six patients were randomly assigned to preoperative medication with lugol's solution. patients in group 1 (n=17) received lugol's solution for 10 days before surgical intervention, whereas patients in group 2 (n=19) didn't receive it. blood flow through the thyroid arteries of patients with graves' disease was measured by color flow doppler ultrasonography. the microvessel density (mvd) was assessed immunohistochemically and western blot analysis using the level of expression of cd-34 in thyroid tissue. the thyroid gland's weight and blood loss were measured in all patients.

Eligibility criteria:
inclusion criteria: * graves disease exclusion criteria: * anticoagulant usage, * previous thyroid operation, * refused to participate in this study.

Keywords: graves' disease, lugol's solution